Michael Egholm - Apr 4, 2023 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
President & CEO, Director
Signature
/s/ Michael Egholm
Stock symbol
LAB
Transactions as of
Apr 4, 2023
Transactions value $
$0
Form type
4
Date filed
4/6/2023, 07:02 PM
Previous filing
Jun 21, 2022
Next filing
Apr 5, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Options Exercise $0 +197K +1965.12% $0.00 207K Apr 4, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Restricted Stock Units Options Exercise $0 -197K -25% $0.00 590K Apr 4, 2023 Common Stock 197K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 5,000 shares of Common Stock purchased pursuant to Fluidigm Corporation (currently Standard BioTools Inc.) 2017 Employee Stock Purchase Plan ("ESPP") for the purchase period of June 1, 2022 to November 30, 2022.
F2 Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.
F3 Restricted Stock Units vest in four equal annual installments beginning April 4, 2023.